Evidence map›Paper›PMID 35336820›Full record

ArticleBiology2022

Rs868058 in the Homeobox Gene

Wioletta Izabela Wujcicka, Marian Kacerovsky, Michał Krekora, Piotr Kaczmarek, Beata Leśniczak, Mariusz Grzesiak

Open access · goldAbstract read
In one paragraph

Article in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Wioletta Izabela WujcickaScientific Laboratory of the Center of Medical Laboratory Diagnostics and Screening, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Marian KacerovskyDepartment of Obstetrics and Gynecology, University Hospital Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic.
Michał KrekoraDepartment of Obstetrics and Gynecology, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Piotr KaczmarekLaboratory of Prenatal Fetal and Maternal Diagnostics, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Beata Leśniczak2nd Department of Gynecology and Obstetrics, Medical University of Lodz, 90-251 Lodz, Poland.
Mariusz GrzesiakDepartment of Gynecology and Obstetrics, Medical University of Lodz, 93-338 Lodz, Poland.ORCID 0000-0002-6900-4347
Medical University of Lodz · PLPolish Mother’s Memorial Hospital Research Institute · PLCharles University · CZ

Funding

Ministry of Science and Higher Education 2018/I/22-SZB
6 · The paper itself

Abstract

Fetal growth restriction (FGR) is a condition that characterizes fetuses as too small for their gestational age, with an estimated fetal weight (EFW) below the 10th percentile and abnormal Doppler parameters and/or with EFW below the 3rd percentile. We designed our study to demonstrate the contribution of single nucleotide polymorphisms (SNPs) from DLX3 (rs11656951, rs2278163, and rs10459948), HLX (rs2184658, and 868058), ANGPT2 (−35 G > C), and ITGAV (rs3911238, and rs3768777) genes in maternal blood in FGR. A cohort of 380 women with singleton pregnancies consisted of 190 pregnancies with FGR and 190 healthy full-term controls. A comparison of the pregnancies with an early-onset FGR and healthy subjects showed that the AT heterozygotes in HLX rs868058 were significantly associated with an approximately two-fold increase in disease risk (p ≤ 0.050). The AT heterozygotes in rs868058 were significantly more frequent in the cases with early-onset FGR than in late-onset FGR in the overdominant model (OR 2.08 95% CI 1.11−3.89, p = 0.022), and after being adjusted by anemia, in the codominant model (OR 2.45 95% CI 1.23−4.90, p = 0.034). In conclusion, the heterozygous AT genotype in HLX rs868058 can be considered a significant risk factor for the development of early-onset FGR, regardless of adverse pregnancy outcomes in women.

Indexed as

angiogenesisFGRHLXhomeobox genespregnancySNP

Identifiers

PMID35336820
PMCPMC8945724
OpenAlexW4220659632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.